NuvaRing (etonogestrel/ethinyl estradiol vaginal ring) FDA Prescribing Information
Merck Sharp & Dohme, 2012
Abstract
No abstract available for this article.
NuvaRing etonogestrel ethinyl estradiol vaginal ring prescribing information, NuvaRing FDA labeling contraindications adverse effects, vaginal ring contraceptive etonogestrel pharmacokinetics, NuvaRing thromboembolism cardiovascular risk prescribing, combined hormonal vaginal ring safety profile warnings, etonogestrel ethinyl estradiol vaginal delivery contraception, NuvaRing package insert drug interactions side effects, vaginal ring hormonal contraceptive venous thrombosis risk, NuvaRing Merck prescribing information clinical pharmacology, combined hormonal contraceptive non-oral delivery system safety
Cite this article
Merck Sharp & Dohme (2012). *NuvaRing (etonogestrel/ethinyl estradiol vaginal ring) FDA Prescribing Information*.
Merck Sharp & Dohme. NuvaRing (etonogestrel/ethinyl estradiol vaginal ring) FDA Prescribing Information. 2012.
Merck Sharp & Dohme. *NuvaRing (etonogestrel/ethinyl estradiol vaginal ring) FDA Prescribing Information*. 2012.